tiprankstipranks
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Germany Market
BRM
Bristol-Myers Squibb
RESEARCH TOOLSreports

Bristol-Myers Squibb (BRM) Stock News & Sentiment

19 Followers
BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
Premium
Company Announcements
BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
8d ago
BMY
The Week That Was, The Week Ahead: Macro and Markets, Mar. 29
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, Mar. 29
16d ago
O
DE
Bristol-Myers Squibb’s Repotrectinib DDI Study: What Investors Should Watch
Premium
Company Announcements
Bristol-Myers Squibb’s Repotrectinib DDI Study: What Investors Should Watch
18d ago
BMY
Milvexian Phase 3 Wraps Up: What Bristol-Myers Squibb Investors Should Watch Next
Premium
Company Announcements
Milvexian Phase 3 Wraps Up: What Bristol-Myers Squibb Investors Should Watch Next
18d ago
BMY
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study
Premium
Company Announcements
Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study
28d ago
BMY
BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis
Premium
Company Announcements
BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis
1M ago
BMY
Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating
Premium
Ratings
Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating
1M ago
BMY
More DE:BRM News >

BRM News on the Web

Market Resilience Amid Geopolitical Tensions: Focus on Rates, Says Cramer
GuruFocus News
Neutral
Jim Cramer says this is the real reason why stocks are shrugging off Iran war fears
CNBC
Neutral
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Zacks
Bullish
Investors Turn to Dividend Stocks Amid Geopolitical Tensions and Oil Price Surge
GuruFocus News
Neutral
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
TipRanks News
Neutral
Which Dividend Pharma Stock Should a Value Investor Choose Today?
The Motley Fool
Bullish
Here are the 3 big things we're watching in the stock market this week
CNBC
Neutral
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
Zacks
Bullish

News Score - Last 7 Days

Positive
DE:BRM
Sector Average
Media Buzz
This Week18 articles
Weekly Average19.75 articles
News Sentiment
This Week100%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:BRM’s Media Buzz Sentiment?
18 articles about DE:BRM were published this week. In an average week, 19.75 articles are published.
    What is DE:BRM’s weekly average amount of articles?
    In an average week, 19.75 articles about DE:BRM are published.
      What is DE:BRM’s News Sentiment?
      100% of articles about DE:BRM were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week